What is Hepion Pharm's earnings per share (EPS)?

Hepion Pharm (CTRVP) reported diluted earnings per share of $-0.88 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hepion Pharm Financials

CTRVP

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Hepion Pharm (CTRVP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Hepion Pharm passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.40x

For every $1 of reported earnings, Hepion Pharm generates $0.40 in operating cash flow (-$3.3M OCF vs -$8.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$8.3M

YoY+37.3%

Hepion Pharm reported -$8.3M in net income in fiscal year 2025. This represents an increase of 37.3% from the prior year.

EPS (Diluted)

$-0.88

Hepion Pharm earned $-0.88 per diluted share (EPS) in fiscal year 2025. This represents an increase of 99.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.8M

YoY+349.8%

5Y CAGR-46.2%

10Y CAGR-8.7%

Hepion Pharm held $1.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

12M

Hepion Pharm had 12M shares outstanding in fiscal year 2025. This represents an increase of 8249.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-310.3%

5Y CAGR-260.1pp

10Y CAGR+106.9pp

Hepion Pharm's ROE was -310.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$446K

YoY-96.2%

5Y CAGR-48.2%

10Y CAGR-25.5%

Hepion Pharm invested $446K in research and development in fiscal year 2025. This represents a decrease of 96.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

CTRVP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$446K-96.2%	$11.8M-66.8%	$35.6M+7.1%	$33.3M+63.1%	$20.4M+70.0%	$12.0M
SG&A Expenses	$3.3M-55.8%	$7.5M-22.0%	$9.6M-7.1%	$10.3M+3.4%	$10.0M+22.8%	$8.1M
Operating Income	-$4.2M+78.5%	-$19.3M+60.1%	-$48.4M-6.5%	-$45.5M-49.6%	-$30.4M-50.9%	-$20.1M
Interest Expense	N/A	N/A	$9K-6.9%	$10K+14.7%	$9K-71.6%	$31K
Income Tax	N/A	-$3.0M-625.9%	-$409K+85.8%	-$2.9M	$0-100.0%	$31K
Net Income	-$8.3M+37.3%	-$13.2M+73.0%	-$48.9M-15.9%	-$42.2M-29.0%	-$32.7M-60.8%	-$20.4M
EPS (Diluted)	$-0.88	$-107.35+82.6%	$-616.07	$-11.90	$-0.47+77.6%	$-2.10

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	$423K+1803.7%	$22K	N/A	$2.8M-61.3%	$7.1M+181.0%	$2.5M
SG&A Expenses	N/A	$528K-42.6%	$919K-26.9%	$1.3M	N/A	$1.7M+24.0%	$1.4M-48.3%	$2.6M
Operating Income	N/A	-$528K+69.8%	-$1.7M-36.3%	-$1.3M	N/A	-$4.5M+47.6%	-$8.5M-64.1%	-$5.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$4K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$3.0M
Net Income	N/A	-$473K+54.7%	-$1.0M+82.9%	-$6.1M	N/A	-$4.9M-24.0%	-$3.9M-37.5%	-$2.9M
EPS (Diluted)	N/A	$-0.04+55.6%	$-0.09+95.8%	$-2.15	N/A	$-36.21-6.5%	$-34.00-20.9%	$-28.13

CTRVP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$3.1M+90.2%	$1.6M-91.1%	$18.1M-70.0%	$60.2M-41.8%	$103.6M+112.9%	$48.6M
Current Assets	$3.1M+90.2%	$1.6M-90.8%	$17.5M-69.0%	$56.5M-42.0%	$97.5M+128.6%	$42.6M
Cash & Equivalents	$1.8M+349.8%	$406K-97.3%	$14.8M-71.1%	$51.2M-44.0%	$91.3M+124.3%	$40.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$0-100.0%	$1.9M0.0%	$1.9M
Total Liabilities	$402K-88.4%	$3.5M-67.8%	$10.8M+4.1%	$10.4M-1.6%	$10.6M+29.9%	$8.1M
Current Liabilities	$299K-90.5%	$3.1M-40.6%	$5.3M-32.9%	$7.9M-3.9%	$8.2M+76.0%	$4.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.7M+243.2%	-$1.9M-125.6%	$7.3M-85.4%	$49.9M-46.4%	$93.0M+129.5%	$40.5M
Retained Earnings	-$246.1M-3.5%	-$237.8M-5.9%	-$224.6M-27.8%	-$175.7M-31.6%	-$133.5M-28.2%	-$104.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$3.1M-17.9%	$3.7M-17.0%	$4.5M-28.7%	$6.3M+291.5%	$1.6M-56.6%	$3.7M-38.2%	$6.0M-62.4%	$16.0M
Current Assets	$3.1M-17.9%	$3.7M-17.0%	$4.5M-28.7%	$6.3M+291.5%	$1.6M-54.3%	$3.5M-35.6%	$5.5M-64.5%	$15.4M
Cash & Equivalents	$1.8M-21.2%	$2.3M-20.6%	$2.9M-36.2%	$4.6M+1028.5%	$406K-72.9%	$1.5M-29.2%	$2.1M-83.9%	$13.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$402K-3.2%	$416K-41.3%	$709K-70.8%	$2.4M-30.3%	$3.5M-15.6%	$4.1M+68.4%	$2.4M-71.1%	$8.5M
Current Liabilities	$299K-13.8%	$347K-41.4%	$593K-36.7%	$936K-70.2%	$3.1M+15.8%	$2.7M+178.4%	$976K-62.1%	$2.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.7M-19.8%	$3.3M-12.4%	$3.8M-2.5%	$3.9M+309.1%	-$1.9M-558.2%	$407K-88.6%	$3.6M-52.6%	$7.5M
Retained Earnings	-$246.1M-0.3%	-$245.4M-0.2%	-$245.0M-0.4%	-$243.9M-2.6%	-$237.8M-0.7%	-$236.3M-2.1%	-$231.4M-1.7%	-$227.5M

CTRVP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$3.3M+82.0%	-$18.2M+55.4%	-$40.9M-17.0%	-$35.0M-12.0%	-$31.2M-93.2%	-$16.2M
Capital Expenditures	N/A	N/A	$14K-12.4%	$16K-87.5%	$130K+48.2%	$88K
Free Cash Flow	N/A	N/A	-$40.9M-16.9%	-$35.0M-11.6%	-$31.4M-92.9%	-$16.3M
Investing Cash Flow	-$132K+78.0%	-$600K-4094.6%	-$14K-1.7%	-$14K+89.2%	-$130K-52.0%	-$86K
Financing Cash Flow	$4.8M+10.9%	$4.3M-3.2%	$4.5M+187.5%	-$5.1M-106.3%	$82.0M+90.4%	$43.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$333K+25.4%	-$446K+67.6%	-$1.4M-23.1%	-$1.1M+3.1%	-$1.2M+54.2%	-$2.5M+77.0%	-$10.9M-202.2%	-$3.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	N/A	N/A	$0	N/A	N/A	$0
Financing Cash Flow	-$160K-1.8%	-$157K-1.8%	-$155K-102.9%	$5.3M	$0-100.0%	$2.5M	$0-100.0%	$1.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CTRVP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-310.3%	N/A	-672.0%-587.4pp	-84.6%-49.5pp	-35.2%+15.0pp	-50.2%
Return on Assets	-269.6%+547.9pp	-817.5%-547.1pp	-270.4%-200.3pp	-70.0%-38.5pp	-31.6%+10.2pp	-41.8%
Current Ratio	10.25+9.7	0.51-2.8	3.31-3.9	7.16-4.7	11.88+2.7	9.15
Debt-to-Equity	0.15+2.0	-1.87-3.4	1.49+1.3	0.21+0.1	0.11-0.1	0.20
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-14.2%+13.3pp	-27.5%+129.3pp	-156.7%	N/A	-1196.5%-1086.3pp	-110.2%-72.3pp	-37.9%
Return on Assets	N/A	-12.6%+10.5pp	-23.1%+73.5pp	-96.6%	N/A	-131.0%-65.7pp	-65.3%-47.5pp	-17.8%
Current Ratio	10.25-0.5	10.77+3.2	7.60+0.8	6.75+6.2	0.51-0.8	1.30-4.3	5.62-0.4	5.99
Debt-to-Equity	0.15+0.0	0.13-0.1	0.19-0.4	0.62+2.5	-1.87-12.0	10.14+9.4	0.69-0.4	1.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is Hepion Pharm profitable?

No, Hepion Pharm (CTRVP) reported a net income of -$8.3M in fiscal year 2025.

What is Hepion Pharm's return on equity (ROE)?

Hepion Pharm (CTRVP) has a return on equity of -310.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Hepion Pharm's operating cash flow?

Hepion Pharm (CTRVP) generated -$3.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Hepion Pharm's total assets?

Hepion Pharm (CTRVP) had $3.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Hepion Pharm spend on research and development?

Hepion Pharm (CTRVP) invested $446K in research and development during fiscal year 2025.

How many shares does Hepion Pharm have outstanding?

Hepion Pharm (CTRVP) had 12M shares outstanding as of fiscal year 2025.

What is Hepion Pharm's current ratio?

Hepion Pharm (CTRVP) had a current ratio of 10.25 as of fiscal year 2025, which is generally considered healthy.

What is Hepion Pharm's debt-to-equity ratio?

Hepion Pharm (CTRVP) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Hepion Pharm's return on assets (ROA)?

Hepion Pharm (CTRVP) had a return on assets of -269.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Hepion Pharm's cash runway?

Based on fiscal year 2025 data, Hepion Pharm (CTRVP) had $1.8M in cash against an annual operating cash burn of $3.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Hepion Pharm's Piotroski F-Score?

Hepion Pharm (CTRVP) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Hepion Pharm's earnings high quality?

Hepion Pharm (CTRVP) has an earnings quality ratio of 0.40x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.